A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
Phase 3
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00219128
- Lead Sponsor
- Novartis
- Brief Summary
Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 671
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change from baseline in diastolic blood pressure after 8 weeks
- Secondary Outcome Measures
Name Time Method Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 4 weeks and 8 weeks Change from baseline in systolic blood pressure after 8 weeks Blood pressure <140/90 mmHg after 4 weeks and 8 weeks Evaluate potential return of hypertension at 4 days and 2 weeks after 8 weeks Evaluate high and low level drug effect using 24 hour blood pressure monitoring
Trial Locations
- Locations (1)
Novartis Pharmaceuticals
🇺🇸East Hanover, New Jersey, United States